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Background
Chemotherapy and Immunotherapy were always consid-
ered incompatible in the treatment of cancer. However,
analysis of sequential use has revealed that there may be
significant additive potential if not synergistic, in enhan-
cing the immune response to cancer.
Material and methods
There are many reasons why chemotherapy may enhance
immune therapy. These include1) the release of tumour
antigens to a primed immune response, 2) the suppression
and reduction of suppressor and regulatory T cells in the
tumour and stromal tissues, 3) The priming of tumour
cells to make them more visible to the immune response,
4) reduction of inflammatory and growth factor drive.
Results
Enhancing the immune response prior to chemotherapy
and releasing antigens as well as stimulating the
immune response after Chemotherapy or radiotherapy
are both effective models. Here we look at specific
examples such as pre-stimulation with non specific
mycobacterial vaccines that will enhance the responses
to gemcitabine and zometa, the former boosting the
Antigen specific responses and the later the gamma
delta T cell activity.
Low dose chemotherapy such as with cyclophospha-
mide or pre vaccine treatment with the IMiDs such as
Revlimid have been shown to enhance the immune
response directly (co-stimlation) and indirectly by
depressing T reg function. Both agents are in therapeutic
vaccine trials for both HIV and Cancer. Another agent
which is anti-inflammatory and immune stimulatory is
low dose naltrexone (LDN) and has been noted to induce
vitiligo in melanoma patient. This has lead to studies
showing that in addition to modulating opiate receptors
on immune cells it is a strong interactor with TLRs.
Conclusions
There are numerous reasons how chemotherapy and
immunotherapy can be additive if not synergistic. The
sequential use of these agents may be more or as impor-
tant as combining them, and the availability of the check
point blockers has added another dimensions as well as
the resurrection of cytokines such as low dose IL-2 for
keeping the effector/memory cells active. There is a good
case to prime with non specific vaccine activators, to then
treat with chemotherapy followed by check point inhibi-
tors and them low dose cytokines , such as IL-2 or other
candidates such as IL-7,12,15, or 21.
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